Selected article for: "high risk and vivo reduction"
Author: Metzger, Vincent T.; Lloyd-Smith, James O.; Weinberger, Leor S.
Title: Autonomous Targeting of Infectious Superspreaders Using Engineered Transmissible Therapies
  • Document date: 2011_3_17
    • ID: 0gt21051_10
    Snippet: For the vaccine, the model assumes optimistic immunization coverage (80% or 95% coverage) of both high-risk and low-risk populations and considers a vaccine that is 30% protective, slightly higher than reported in the recent 'Thai trial' [34] , or a hypothetical 50% protective vaccine; life-long efficacy is assumed for both vaccines (i.e. no HIV mutational escape) but not for the TIP. For the TIPs, we analyze interventions that generate a 0.5-Log.....
    Document: For the vaccine, the model assumes optimistic immunization coverage (80% or 95% coverage) of both high-risk and low-risk populations and considers a vaccine that is 30% protective, slightly higher than reported in the recent 'Thai trial' [34] , or a hypothetical 50% protective vaccine; life-long efficacy is assumed for both vaccines (i.e. no HIV mutational escape) but not for the TIP. For the TIPs, we analyze interventions that generate a 0.5-Log to 1.5-Log viral-load reduction in vivo, as reported in a recent HIV gene-therapy trial [17] . The model predicts the effects of vaccination or TIP intervention on HIV/AIDS prevalence in a resource-poor sub-Saharan setting.

    Search related documents:
    Co phrase search for related documents
    • gene therapy and HIV AIDS prevalence: 1, 2
    • gene therapy and low risk: 1, 2, 3
    • gene therapy and low risk high risk: 1
    • gene therapy and protective vaccine: 1, 2
    • gene therapy and tip intervention: 1, 2
    • gene therapy trial and high risk: 1
    • gene therapy trial and HIV AIDS prevalence: 1, 2
    • gene therapy trial and protective vaccine: 1
    • gene therapy trial and tip intervention: 1, 2
    • high risk and HIV AIDS prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • high risk and HIV mutational escape: 1
    • high risk and immunization coverage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • high risk and low risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • high risk and low risk high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • high risk and low risk high risk population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • high risk and mutational escape: 1
    • high risk and protective vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • high risk and sub saharan setting: 1
    • high risk and tip intervention: 1, 2, 3, 4